10.3389/fnmol.2024.1400118 50 GarciaM
Wird die erfindungsgeme wasserlsliche Zusammensetzung in eine wssrige Lsung zur Verabreichung bergefhrt, sollte die Konzentration des pharmazeutisch wirksamen Peptidsalzes in der Lsung vorzugsweise etwa 0,0000001 bis 10% (Gew./Vol.), mehr bevorzugt etwa 0,000001 bis 5% (Gew./Vol.) oder besonders bevorzugt etwa 0,00001 bis 1% (Gew./Vol.) betragen
L-carnitine is given to patients receiving dialysis for kidney failure and is considered very safe.L-carnitine (LC) administration has been recommended for specific indications in dialysis patients, including epoetin-resistant anemia, intradialytic hypotension, cardiomyopathy, fatigue, muscle weakness, and exercise performance
Initial clinical evidence suggests that GLP-1s may help in three key areas: 1
However, it is encouraging that a recent assessment of an inactivated SARS-CoV-2 vaccine elicited strong neutralizing antibodies in mice, rats and rhesus macaques, and provided dose-dependent protection without evidence of enhanced pathology in rhesus macaques 74